Merck (MRK) Announces Positive Phase 3 SMART Trial Results for ENFLONSIA (Clesrovimab)
Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks to buy now.
Merck Sharp & Dohme Corp. (MRK)
This company is not actively trading or the ticker does belong to another company in our database now. The symbol (MRK) is currently associated with the following stock: Merck & Co. Inc. (MRK)
Sector: Pharmaceutical Preparations
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.22 | 550 | $18,268.75 | 750 | 2006-01-18 | Filing | |
| $45.65 | 200 | $9,130.56 | 200 | 2002-09-24 | Filing |
News See All
11 Best Value Stocks to Buy Now
On February 7, Richard Bernstein, the CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the current state of the equity markets and his firm's macro-driven investment strategy...
Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation
On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price target on the stock.
14 Best Low Volatility Dividend Stocks to Invest In
Morgan Stanley’s Global Investment Committee believes the current bull market still has room to run and could extend into a fourth year.
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff
On February 13, Deutsche Bank analyst James Shin upgraded Merck & Co., Inc. (NYSE:MRK) to Buy from Hold. The analyst raised his price target on the stock to $150 from $115.
16 Best Dividend Stocks with Rising Payouts
CNBC reported that investors trying to protect themselves from risks tied to artificial intelligence may want to look at dividend-paying stocks, according to Jenny Harrington, CEO of Gilman Hill Asset...
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results
Impax Asset Management's "Impax US Sustainable Economy Fund" released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+
Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.
Hedge Fund Resource Center